Fig. 9

Promotion of CRC cell aggressiveness was abrogated when CLCA1-KO cells were co-treated with XAV939. a The promotion of CRC cell growth was abrogated when CLCA1-KO cells were co-treated with XAV939. b The enhancement CRC cell migration and invasion was abrogated when CLCA1-KO cells were co-treated with XAV939 (left panel, representative pictures of transwell chambers; right panel, average counts of five random microscopic fields at a magnification of 200×). *P < 0.05, t-test; **P < 0.01, t-test